CD19 and diffuse large B-cell lymphoma: In 2017, the first two CD19-directed CAR-T therapies, tisagenlecleucel and axicabtagene ciloleucel, were approved by the Food and Drug Administration (FDA) and subsequently the European Medicines Agency (EMA) to treat patients with diffuse large B-cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukaemia (B-ALL).